About Immunovia

Company Description

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1.

Year founded

2007

Headquarters

Scheelevägen 2, 22381 Lund – Sweden

Shareholder information

Shares outstanding

22,631,581

IPO

Jan. 1, 2000

Stock exchange(s)

Nasdaq Stockholm

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.